← Back to Clinical Trials
Recruiting NCT07422506

NCT07422506 A Real-World Study Comparing the Efficacy of Different Treatment Regimens for Early Missed Abortion

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07422506
Status Recruiting
Phase
Sponsor The Third Xiangya Hospital of Central South University
Condition Missed Abortion
Study Type INTERVENTIONAL
Enrollment 580 participants
Start Date 2024-01-01
Primary Completion 2030-01-01

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age 40 Years
Study Type INTERVENTIONAL
Interventions
Control groupConventional dose of estrogenHigh-dose estrogen

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 580 participants in total. It began in 2024-01-01 with a primary completion date of 2030-01-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

At present, there is no unified standard for the treatment of missed abortion in clinical practice. This study intends to collect clinical data of this type of disease to compare the efficacy of different treatments, and on this basis, presuppose the synergistic effect of different doses of estrogen in the process of drug induction, conduct statistical analysis of the efficacy, evaluate whether the treatment plan can achieve the therapeutic effect while reducing the occurrence of complications, and provide an effective basis for the subsequent clinical treatment of missed abortion. This study is divided into two parts. The first part is a retrospective analysis to explore the differences between missed abortion surgery and drug treatment, clinical efficacy and reproductive outcomes; the second part is a prospective study to explore the effects of different doses of estrogen combined with surgery or drug abortion on the efficacy of missed abortion in early pregnancy, and explore the best clinical treatment method for missed abortion.

Eligibility Criteria

Inclusion Criteria: * ①Age 18-40 years old; ②Early pregnancy missed abortion confirmed by imaging and laboratory tests; ③All indicators of routine examinations before treatment are within the normal range, and there are no serious systemic diseases; ④No indications for emergency curettage; ⑤Good compliance, follow-up observation as required (prospective study). Exclusion Criteria: * ①Contraindications to medical abortion; ②Those who are allergic to estrogen and have contraindications to the use of estrogen; ③Those who cannot be followed up according to the follow-up plan; ④Thromboembolic diseases, known or suspected history of breast cancer, hormone-dependent tumors, etc.; ⑤Vaginal bleeding exceeds the usual menstrual volume; ⑥Those with severe heart, liver and kidney diseases; ⑦Accompanied by serious internal and surgical diseases, malignant tumors or mental illnesses, and cannot cooperate.

Contact & Investigator

Central Contact

Dabao Xu

✉ forxudabao@126.com

📞 13017386201

Frequently Asked Questions

Who can join the NCT07422506 clinical trial?

This trial is open to female participants only, aged 18 Years or older, up to 40 Years, studying Missed Abortion. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07422506 currently recruiting?

Yes, NCT07422506 is actively recruiting participants. Contact the research team at forxudabao@126.com for enrollment information.

Where is the NCT07422506 trial being conducted?

This trial is being conducted at Changsha, China.

Who is sponsoring the NCT07422506 clinical trial?

NCT07422506 is sponsored by The Third Xiangya Hospital of Central South University. The trial plans to enroll 580 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology